이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Legend Biotech 관리

관리 기준 확인 2/4

Legend Biotech's CEO는 Ying Huang, Sep2020 에 임명되었습니다 의 임기는 3.75 년입니다. 는 $ 2.60M 가치에 해당하는 회사 주식의 0.035% 직접 소유합니다. 2.60M. 경영진과 이사회의 평균 재임 기간은 각각 2.1 년과 3 년입니다.

주요 정보

Ying Huang

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	4yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30

CEO

Ying Huang (51 yo)

4yrs

테뉴어

Dr. Ying Huang, Ph D., had been Chief Financial Officer of Legend Biotech Corporation since July 2019 until May 09, 2022 and was its Interim Chief Executive Officer since September 21, 2020 until November...

리더십 팀

이름	위치	테뉴어	보상	소유권
Ying Huang	CEO & Director	4yrs	데이터 없음	0.035% $ 3.2m
Lori Macomber	Chief Financial Officer	2.3yrs	데이터 없음	0.0031% $ 276.9k
Doug Wallace	Vice President of Global Operations	less than a year	데이터 없음	데이터 없음
Guowei Fang	Chief Scientific Officer & Head of Business Development	no data	데이터 없음	데이터 없음
Joanne Choi	Senior Manager of Investor Relations	no data	데이터 없음	데이터 없음
James Pepin	General Counsel	less than a year	데이터 없음	데이터 없음
Tim Roberts	Global Compliance Officer	less than a year	데이터 없음	데이터 없음
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	no data	데이터 없음	데이터 없음
Elaine Qian	VP & Global Head of Human Resources	1.4yrs	데이터 없음	데이터 없음
Yuhong Qiu	Senior Vice President of Global Regulatory Affairs	2.7yrs	데이터 없음	데이터 없음
Steven Gavel	Senior Vice President of Commercial Development	2.7yrs	데이터 없음	데이터 없음
Alan Kick	Senior Vice President of Global Quality	2.7yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

경험이 풍부한 관리: LEGN 의 관리팀은 경험 ( 2.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Ying Huang	CEO & Director	2.8yrs	데이터 없음	0.035% $ 3.2m
John M. Maraganore	Member of Strategic Advisory Board	1.4yrs	데이터 없음	데이터 없음
Li Zhu	Non-Independent Director	3.8yrs	데이터 없음	데이터 없음
Corazon Sanders	Independent Director	4.3yrs	데이터 없음	0.010% $ 946.1k
Xiaohui Ji	Independent Director	4.3yrs	데이터 없음	0.0050% $ 454.0k
Tomas Heyman	Independent Director	2.1yrs	데이터 없음	0.0011% $ 99.9k
Fangliang Zhang	Independent Chairman	2.1yrs	데이터 없음	0% $ 0
Ye Wang	Director	9.3yrs	데이터 없음	0% $ 0
Michel Vounatsos	Member of Strategic Advisory Board	1.4yrs	데이터 없음	데이터 없음
Wai Man Yau	Independent Director	4.3yrs	데이터 없음	0.0010% $ 92.6k
Patrick Casey	Independent Director	3.8yrs	데이터 없음	0.0069% $ 623.8k
Li Mao	Independent Director	2.1yrs	데이터 없음	0.0019% $ 170.7k

3.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: LEGN 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Legend Biotech 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Recent updates

Legend Biotech Corporation, Annual General Meeting, Oct 21, 2024

Chief Financial Officer notifies of intention to sell stock

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Legend Biotech Achieves Breakthrough with Cilta-Cel Approval in China, Offering New Hope for Multiple Myeloma Patients

Consensus estimates of losses per share improve by 33%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Legend Biotech Corporation Appoints Peter Salovey as Independent Director, Effective August 9, 2024

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech Corporation Announces Positive Overall Survival Results of Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Legend Biotech stock slides on proposed ADS offering

Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901